These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 16865210)

  • 1. Cardiac disease in beta-thalassaemia major: Is it reversible?
    Atiq M; Bana M; Ahmed US; Bano S; Yousuf M; Fadoo Z; Khurshid M
    Singapore Med J; 2006 Aug; 47(8):693-6. PubMed ID: 16865210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac status in well-treated patients with thalassemia major.
    Aessopos A; Farmakis D; Hatziliami A; Fragodimitri C; Karabatsos F; Joussef J; Mitilineou E; Diamanti-Kandaraki E; Meletis J; Karagiorga M
    Eur J Haematol; 2004 Nov; 73(5):359-66. PubMed ID: 15458515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pulmonary hypertension in thalassaemia major patients with normal left ventricular systolic function.
    Hagar RW; Morris CR; Vichinsky EP
    Br J Haematol; 2006 May; 133(4):433-5. PubMed ID: 16643452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac study by dobutamine stress echocardiography in thalassemic patients.
    Mariotti E; Agostini A; Angelucci E; Cesaroni P; Lucarelli G; Sgarbi E
    Bone Marrow Transplant; 1993; 12 Suppl 1():14-5. PubMed ID: 8374553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Beta-thalassemia in Germany. Results of cooperative beta-thalassemia study].
    Cario H; Stahnke K; Kohne E
    Klin Padiatr; 1999; 211(6):431-7. PubMed ID: 10592921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival in medically treated patients with homozygous beta-thalassemia.
    Olivieri NF; Nathan DG; MacMillan JH; Wayne AS; Liu PP; McGee A; Martin M; Koren G; Cohen AR
    N Engl J Med; 1994 Sep; 331(9):574-8. PubMed ID: 8047081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of thalassemia treated with conventional therapy.
    Borgna-Pignatti C; Zurlo MG; DeStefano P; Boffa C; DeSanctis V; DiPalma A; DiGregorio L; Melevendi C; Piga A; Sabato V
    Bone Marrow Transplant; 1993; 12 Suppl 1():2-4. PubMed ID: 8374554
    [No Abstract]   [Full Text] [Related]  

  • 8. Prevalence of endocrine complications in beta-thalassaemia major in the Islamic Republic of Iran.
    Karamifar H; Shahriari M; Sadjadian N
    East Mediterr Health J; 2003; 9(1-2):55-60. PubMed ID: 15562733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac and pulmonary dysfunction in asymptomatic beta-thalassanemia major.
    Noori NM; Keshavarz K; Shahriar M
    Asian Cardiovasc Thorac Ann; 2012 Oct; 20(5):555-9. PubMed ID: 23087299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology and chelation therapy effects on glucose homeostasis in thalassaemic patients.
    Gamberini MR; Fortini M; Gilli G; Testa MR; De Sanctis V
    J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():867-9. PubMed ID: 10091159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF).
    De Sanctis V; Eleftheriou A; Malaventura C;
    Pediatr Endocrinol Rev; 2004 Dec; 2 Suppl 2():249-55. PubMed ID: 16462705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe infections in thalassaemic patients: prevalence and predisposing factors.
    Rahav G; Volach V; Shapiro M; Rund D; Rachmilewitz EA; Goldfarb A
    Br J Haematol; 2006 Jun; 133(6):667-74. PubMed ID: 16704445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spermatogenesis in young adult patients with beta-thalassaemia major long-term treated with desferrioxamine.
    De Sanctis V; Borsari G; Brachi S; Govoni M; Carandina G
    Georgian Med News; 2008 Mar; (156):74-7. PubMed ID: 18403814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological and radiological study of Egyptian β-thalassemia intermedia and β-thalassemia major patients: relation to complications and response to therapy.
    Mokhtar GM; Tantawy AA; Adly AA; Ismail EA
    Hemoglobin; 2011; 35(4):382-405. PubMed ID: 21797705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical management of cardiovascular complications in patients with thalassaemia major: a large observational multicenter study.
    Derchi G; Formisano F; Balocco M; Galanello R; Bina P; Dessì C; Piga A; Donato G; Cappellini MD; Cassinerio E; Quarta G; Melpignano A; Forni GL
    Eur J Echocardiogr; 2011 Mar; 12(3):242-6. PubMed ID: 21278193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Celiac disease associated with major thalassemia. A case report].
    Mangiagli A; Campisi S
    Minerva Pediatr; 1996 Sep; 48(9):401-5. PubMed ID: 8992285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chelation therapy with desferrioxamine does not normalize ferritin level but attenuates oxidative damage and improves total antioxidant level in Malaysian Chinese beta-thalassaemia major patients.
    Kuppusamy UR; Tan JA
    West Indian Med J; 2011 Jan; 60(1):3-8. PubMed ID: 21809703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Desferrioxamine therapy induces clearance of iron deposits after bone marrow transplantation for thalassemia: case report.
    Giardini C; La Nasa G; Contu L; Galimberti M; Polchi P; Angelucci E; Baronciani D; Barbanti I; Muretto P; Lucarelli G
    Bone Marrow Transplant; 1993; 12 Suppl 1():108-10. PubMed ID: 8374548
    [No Abstract]   [Full Text] [Related]  

  • 19. Self-reported level of and factors influencing the compliance to desferrioxamine therapy in multitransfused thalassaemias.
    Lee WS; Toh TH; Chai PF; Soo TL
    J Paediatr Child Health; 2011 Aug; 47(8):535-40. PubMed ID: 21392144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucose tolerance and beta-cell secretion in patients with thalassaemia major.
    Mangiagli A; Italia S; Campisi S
    J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():985-6. PubMed ID: 10091179
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.